The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
Abstract
Objective: Chronic inflammatory conditions such as rheumatoid arthritis (RA) have been associated with malignant lymphomas. This study was undertaken to investigate which patients are at highest risk, and whether antirheumatic treatment is hazardous or protective. Methods: We performed a matched case–control study of 378 consecutive Swedish RA patients in whom malignant lymphoma occurred between 1964 and 1995 (from a population‐based RA cohort of 74,651 RA patients), and 378 controls. Information on disease characteristics and treatment from onset of RA until lymphoma diagnosis was abstracted from medical records. Lymphoma specimens were reclassified and tested for Epstein‐Barr virus (EBV). Relative risks (odds ratios [ORs]) for lymphomas (by subtype) associated with deciles of cumulative disease activity were assessed, as were ORs associated with drug treatments. Results: The relative risks of lymphoma were only modestly elevated up to the seventh decile of cumulative disease activity. Thereafter, the relative risk increased dramatically (OR ninth decile 9.4 [95% confidence interval 3.1–28.0], OR tenth decile 61.6 [95% confidence interval 21.0–181.0]). Most lymphomas (48%) were of the diffuse large B cell type, but other lymphoma subtypes also displayed an association with cumulative disease activity. Standard nonbiologic treatments did not increase lymphoma risk. EBV was present in 12% of lymphomas. Conclusion: Risk of lymphoma is substantially increased in a subset of patients with RA, those with very severe disease. High inflammatory activity, rather than its treatment, is a major risk determinant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS
STEINBROCKER, O. (1949) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1949.02900430001001 · Cited by 2,877
Vitali, C., Bombardieri, S., Moutsopoulos, H. M., Balestrieri, G., Bencivelli, W., Bernstein, R. M., Bjerrum, K. B., Braga, S., Coll, J., Vita, S. D., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360309 · Cited by 1,436
Brown, S. L., Greene, M. H., Gershon, S. K., Edwards, E. T., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10679 · Cited by 655
Wolfe, F., & Michaud, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20311 · Cited by 644
Incidence of Cancer Among Patients With Rheumatoid Arthritis
Gridley, G., McLaughlin, J. K., Ekbom, A., Klareskog, L., Adami, H.-O., Hacker, D. G., Hoover, R., & Fraumeni, J. F. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.307 · Cited by 581
Self-citationMattsson, B., & Wallgren, A. (1984) · Acta Radiologica: Oncology · doi:10.3109/02841868409136026 · Cited by 559
Mariette, X. (2002) · Blood · doi:10.1182/blood.v99.11.3909 · Cited by 428
Baecklund, E., Ekbom, A., Sparén, P., Feltelius, N., & Klareskog, L. (1998) · BMJ · doi:10.1136/bmj.317.7152.180 · Cited by 394
Self-citationSalloum, E., Cooper, D. L., Howe, G., Lacy, J., Tallini, G., Crouch, J., Schultz, M., & Murren, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1943 · Cited by 380
Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies.
Greenstein, S., Ghias, K. K., Krett, N. L., & Rosen, S. T. (2002) · PubMed · Cited by 279
Silman, A. J., Petrie, J., Hazleman, B., & Evans, S. J. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.12.988 · Cited by 276
Dayharsh, G. A., Loftus, E. V., Sandborn, W. J., Tremaine, W. J., Zinsmeister, A. R., Witzig, T. E., Macon, W. R., & Burgart, L. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.30328 · Cited by 275
Ekström, K., Hjalgrim, H., Brandt, L., Baecklund, E., Klareskog, L., Ekbom, A., & Askling, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10939 · Cited by 267
Self-citationThe relationship between infliximab treatment and lymphoma in Crohn's disease
Bickston, S. J., Lichtenstein, G. R., Arseneau, K. O., Cohen, R. B., & Cominelli, F. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70294-5 · Cited by 203
Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
Fraser, A. G., Orchard, T. R., Robinson, E. M., & Jewell, D. P. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01297.x · Cited by 198
Kamel, O. W., van de Rijn, M., LeBrun, D. P., Weiss, L. M., Warnke, R. A., & Dorfman, R. F. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90295-x · Cited by 185
Thomas, E., Symmons, D. P. M., Brewster, D. H., Black, R. J., & Macfarlane, G. J. (2003) · PubMed · Cited by 182
Baecklund, E., Sundström, C., Ekbom, A., Catrina, A. I., Biberfeld, P., Feltelius, N., & Klareskog, L. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11144 · Cited by 180
Self-citationSorensen, H. T., Mellemkjaer, L., Nielsen, G. L., Baron, J. A., Olsen, J. H., & Karagas, M. R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh118 · Cited by 171
Cancer morbidity in rheumatoid arthritis.
Prior, P., Symmons, D. P., Hawkins, C. F., Scott, D. L., & Brown, R. (1984) · Annals of the Rheumatic Diseases · doi:10.1136/ard.43.2.128 · Cited by 162
Zhang, Y., Holford, T. R., Leaderer, B. P., Zahm, S. H., Boyle, P., Morton, L. M., Zhang, B., Zou, K., Flynn, S. D., Tallini, G., et al. (2004) · Cancer Causes & Control · doi:10.1023/b:caco.0000027506.55846.5d · Cited by 152
Cerhan, J. R., Anderson, K. E., Janney, C. A., Vachon, C. M., Witzig, T. E., & Habermann, T. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11311 · Cited by 71
Zijlstra, T. R., Moens, H. J. B., & Bukhari, M. A. S. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.1.20 · Cited by 56
Cited by
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
“5) In 40 of the 386 cases with lymphoma, medical records did not include enough information to evaluate whether the RA criteria of the American College of Rheumatology were fulfilled but all available information supported the diagnosis of RA Baecklund [22] 16508929 2006 MR”
BackgroundInfluentialSelf-citationSmolen, J. S., Aletaha, D., & McInnes, I. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30173-8 · Cited by 4,870
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Self-citationBeaugerie, L., Brousse, N., Bouvier, A. M., Colombel, J. F., Lémann, M., Cosnes, J., Hébuterne, X., Cortot, A., Bouhnik, Y., Gendre, J. P., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61302-7 · Cited by 1,115
Metadata
- Authors
- Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., & Klareskog, L.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-02-28
- Volume
- 54
- Issue
- 3
- Pages
- 692-701
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1977445011
- Cited by
- 890
- References
- 26
- FWCI
- 31.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.